about
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanomaNVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivoMain roads to melanomaMelanoma: from melanocyte to genetic alterations and clinical optionsDiagnostic role of chromosomal instability in melanomaTumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitorsIdentification and functional characterization of FMN2, a regulator of the cyclin-dependent kinase inhibitor p21Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazineThe chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4aGermline mutations in BAP1 predispose to melanocytic tumorsAnalysis of the genome to personalize therapy for melanomaA landscape of driver mutations in melanomaExome sequencing identifies recurrent somatic RAC1 mutations in melanomaIntegrative analysis of the melanoma transcriptomeBRAF mutations in hairy-cell leukemiaMelanoma genome sequencing reveals frequent PREX2 mutationsThe histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onsetImproved survival with vemurafenib in melanoma with BRAF V600E mutationFrequent somatic mutations of GNAQ in uveal melanoma and blue naeviPersonalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker SelectionRecent advances in molecular genetics of melanoma progression: implications for diagnosis and treatmentTime to reconsider Spitzoid neoplasms?Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ systemClinical utility of nivolumab in the treatment of advanced melanomaChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)cfDNA analysis from blood in melanomaMelanoma: oncogenic drivers and the immune systemCan Peto's paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical reviewAmeloblastoma: A Review of Recent Molecular Pathogenetic DiscoveriesMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsTargeting the Checkpoint to Kill Cancer CellsIpilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaTargeting NADPH oxidases for the treatment of cancer and inflammationMelanoma. Shall we move away from the sun and focus more on embryogenesis, body weight and longevity?Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancerProgression of cutaneous melanoma: implications for treatmentNew treatments for metastatic melanomaMelanoma: from mutations to medicineSignaling cross-talk in the resistance to HER family receptor targeted therapyNUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.
P2860
Q21093253-DED20915-3C4F-4F91-9EF7-1013D8895AC7Q21132689-B06EA0F3-9DB5-429F-91BF-DCD39EC99AD1Q21245465-C2572368-D476-4109-B276-248F9722A752Q21284811-4E6B6923-074D-4F28-828B-764369448125Q21285151-C8895B16-D5F6-4F7E-9DED-0FAAB5577F98Q24306212-669F667D-B797-4046-A3A0-4CD59663C80BQ24313202-36B311C7-531A-4BA5-AB63-688CD42E0AA9Q24313552-B32F7A19-633A-4453-BF66-8BA165B714D0Q24317334-3B8E8531-B4ED-4446-8984-9988C0151BB2Q24594891-C6080C5A-097D-414F-A537-FD94B06847BBQ24601008-E8DFD343-00EF-4929-85BC-5B6CF7B133A2Q24603357-4072F900-37AF-4001-88D6-3DC49A250933Q24607661-B9B5DE09-CCC7-4731-A38B-A626FD10F1BFQ24608060-643B35CE-6803-4BD8-8CD7-179BE3A5BB0EQ24609980-901DA0DE-C00D-41A4-9A36-3E29C5C05375Q24610463-3E49691B-E5DF-44B9-85E1-FA74B9781F2FQ24625220-C48BBFCC-47B0-4E18-AF6D-F9E3F1EFC42CQ24631953-C512C94B-DE35-40E2-930D-48F81C89F63CQ24646052-FD553E96-0BCC-400B-9F49-CE9D76B8C002Q26738860-BD6B99DD-7350-42FF-88A0-A9DC744E2B8BQ26740631-5E39DB7A-0181-4271-B429-F32954CDB393Q26746017-9B372ADD-68C6-46F5-B1C4-130079FC04B7Q26748510-F0FD26D1-F90F-418E-9598-F16E31957B7DQ26751268-D2CAD609-4211-42B3-831A-B62F4F076D2AQ26770492-04B49B22-9ABD-485E-8B37-1AF08B188470Q26772199-0130F9CD-C7F3-4CF1-882E-6223FF5B3220Q26775598-5DE1253E-D9D7-41EA-B045-0FB4677E0058Q26779417-AABF527B-B1EC-4989-9886-B6D7B867B3F7Q26781648-5341B9F7-61FF-4682-B72D-63D400599D40Q26795735-86FB8487-B123-4593-A779-10D29777A167Q26795781-968D4D3E-8C8C-4213-B264-A7097F83523DQ26824310-99278335-F566-4D83-86C7-64D800D32FE4Q26851163-48F97C1F-76BE-4989-A2E7-76D1B97DFEFDQ26853315-A5297449-3792-4FAD-93CC-CBB612EE56F7Q26863418-531329DE-CDF7-4DC7-B68A-BC5E74A977B4Q27001734-A01135F2-09CB-4FF1-B276-680EF13858C6Q27007068-F441DD99-451B-4FE2-A149-348BD7447617Q27024061-70C1372F-F2BD-4CE6-BCDC-754F9688DCDBQ27027778-DF155068-53FB-4854-825D-64BEFA92B149Q27348507-4BE6DF26-612A-4E57-A75A-C740A26E657C
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Distinct sets of genetic alterations in melanoma
@ast
Distinct sets of genetic alterations in melanoma
@en
type
label
Distinct sets of genetic alterations in melanoma
@ast
Distinct sets of genetic alterations in melanoma
@en
prefLabel
Distinct sets of genetic alterations in melanoma
@ast
Distinct sets of genetic alterations in melanoma
@en
P2093
P3181
P356
P1476
Distinct sets of genetic alterations in melanoma
@en
P2093
Dan Pinkel
Eva-Bettina Bröcker
Heinz Kutzner
Hetal N Patel
Jane Fridlyand
Klaus J Busam
Kwang-Hyun Cho
Philip E LeBoit
Setsuya Aiba
Toshiro Kageshita
P304
P3181
P356
10.1056/NEJMOA050092
P407
P577
2005-11-01T00:00:00Z